Safety Profile
EPO
Updated today
Erythropoiesis GlycoproteinHow we score compound safety →
Regulatory Status
Safety Summary
- Safe ONLY in its monitored clinical indication (anemia, hematology-supervised). In non-anemic / endurance / performance use it raises hematocrit and carries serious thromboembolic risk — stroke, MI, pulmonary embolism, sudden death
- historically linked to a cluster of endurance-athlete fatalities. Black-box warning in oncology. Rated low because the relevant real-world use here is high-risk and unmonitored.
EPO's 3/10 rating is in our caution tier. Either documented side-effect patterns are concerning, the human safety dataset is too thin to make confident statements, or the compound is under active regulatory scrutiny. We recommend reviewing the full notes above and consulting a licensed physician before any research use. Researchers often consider HGH 191AA (Somatropin) as alternatives in the same category — see the related-compounds section below for safety comparisons.
Molecular Profile
Storage
- Biologic — do NOT freeze
- Do not shake
- Protect from light
Related Compounds
Methodology
How we rate peptide safety
Every compound in our index gets a 1–10 safety score based on four weighted factors. The score reflects known research-use risk — not medical advice.
- 40% — Clinical evidence. Volume of peer-reviewed trials, sample sizes, duration, and consistency of outcomes. FDA-approved compounds anchor the top end (8–10); preclinical-only compounds cap at 6.
- 30% — Adverse-event profile. Severity and frequency of reported side effects, including GI events, cardiovascular signals, hypoglycemia, and long-term organ effects.
- 20% — Regulatory status. FDA approval, EMA approval, or status in active clinical trials. Compounds under safety warnings are penalized.
- 10% — Community-reported outcomes. Reddit, forum, and published case-report signal beyond formal trials. Used as a late-stage tiebreaker, not a leading factor.
Related compounds
Other compounds researchers compare with EPO
Safety ratings are derived from published clinical data, FDA approval status, and community-reported outcomes. They are not medical advice. Always consult a healthcare professional before using any research compound.
